A Phase 2 interventional study of Brepocitinib in Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis and Non-infectious Pan Uveitis, sponsored by Priovant Therapeutics, Inc.. Completed at 15 sites in United States. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-07-25.
Sponsored by Priovant Therapeutics, Inc. · Phase 2, Interventional, and Other
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).
Active uveitic disease as defined by the presence of at least 1 of the following parameters in at least 1 eye, as determined by the investigator:
Exclusion Criteria:
History of:
Other protocol defined Inclusion/Exclusion criteria may apply
Drug: Brepocitinib
Drug: Brepocitinib
Oral Brepocitinib
Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Safety assessments will consist of monitoring and recording all adverse events (AEs) and SAEs, laboratory evaluation for hematology, blood chemistry, and urinalysis; vital signs; electrocardiograms (ECGs); and physical examinations. The investigator will determine whether the change is clinically meaningful.
Time frame: Screening up to 28 days after the last dose of study drug at 52 weeks
Proportion of participants meeting treatment failure criteria on or after Week 6 up to Week 24
Time frame: 24 weeks
Plan to share: Yes — Priovant Therapeutics will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) from eligible studies upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Data requests will be reviewed and approved on the basis of scientific merit.
Supporting information: Study protocol, Sap, Csr
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Priovant Therapeutics, Inc.